Advertisement

Rafael Pharmaceuticals receives FDA Orphan Drug Designation of CPI-613 for peripheral T-cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rafael Pharmaceuticals Inc. said FDA has granted an orphan drug designation to CPI-613, the company’s lead Altered Energy Metabolism Directed drug candidate, for the treatment of peripheral T-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement